• Facets (new session)
• Description
• Metadata
• Settings
  • Rule: ActivityStreamsMapasEquivalentb3sb3sifpdbprdf-labelfacetshttp://dbpedia.org/resource/inference/rules/dbpedia#http://dbpedia.org/resource/inference/rules/opencyc#http://dbpedia.org/resource/inference/rules/umbel#http://dbpedia.org/resource/inference/rules/yago#http://dbpedia.org/schema/property_rules#http://www.ontologyportal.org/inference/rules/SUMO#http://www.ontologyportal.org/inference/rules/WordNet#http://www.w3.org/2002/07/owl#ldpoplwebskos-transurn:det:rdf:labelvirtrdf-labelvirtrdf-urlNone
    
  • Inverse Functional Properties: Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects
  • "Same As": Disabled (fastest) Apply to subjects only Apply to objects only Apply to both subjects and objects (recommended) Apply to subjects, objects and predicates (not recommended on big datasets) Apply to predicates only (special use cases only)

About: The Billion-Dollar Molecule     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : yago:Whole100003553, within Data Space : dbpedia.org associated with source document(s)

Type: Thingbibo:Bookschema:Bookschema:CreativeWorkworkText (literary theory)wikidata:Q386724Bookyago:WikicatBooksAboutCompaniesyago:WikicatBusinessBooksyago:WikicatScienceBooksyago:Artifact100021939yago:Book106410904yago:Creation103129123yago:Object100002684yago:PhysicalEntity100001930yago:Product104007894yago:Publication106589574yago:Work104599396bookwritten workyago:Whole100003553 New Facet based on Instances of this Class

The Billion-Dollar Molecule is a book by journalist Barry Werth about the founding and early research efforts of the American biotechnology company Vertex Pharmaceuticals, which was founded in 1989 by Joshua Boger and was among the first biotechnology companies to adopt an explicit strategy of rational drug design as opposed to techniques based on combinatorial chemistry. This book is notable as an inside look at a biotechnology company, and the stresses and marketing pressures on funding research into drug design. This book is a mixture of finance and technology.